Deuterated Organic Compounds for Schizophrenia and Depression Treatment
Summary
The USPTO published patent application US20260098011A1 covering deuterated organic compounds of Formula I and II for modulating dopamine and serotonin neurotransmission. The compounds are directed toward treating disorders including schizophrenia and depression. The application was filed on June 11, 2025, under application number 19235237.
What changed
The USPTO published patent application US20260098011A1 disclosing deuterated organic compounds of Formula I and II useful for modulating dopamine and serotonin neurotransmission. The compounds are directed toward treating schizophrenia, depression, and related neuropsychiatric disorders. The application includes processes for compound preparation, pharmaceutical compositions, and therapeutic uses.
Pharmaceutical companies and biotech firms developing neuropsychiatric treatments should review this publication to assess potential overlaps with their own R&D programs and freedom-to-operate positions. The deuterated compound approach may offer IP differentiation opportunities for drug developers targeting CNS disorders. Clinical development and regulatory approval would be required before any therapeutic use.
What to do next
- Monitor patent prosecution for claims scope
- Review therapeutic applications in neuropsychiatric drug pipelines
- Assess IP landscape for deuterated compound innovations
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
DEUTERATED ORGANIC COMPOUNDS AND USES THEREOF
Application US20260098011A1 Kind: A1 Apr 09, 2026
Inventors
Krishna VADODARIA, Kimberly VANOVER, Vikram SUDARSAN, David GARVEY
Abstract
Provided are compounds of Formula I and Formula II, described herein, processes for their preparation, their use as pharmaceuticals, and pharmaceutical compositions comprising them and intermediates used in their preparation. Compounds of Formula I and Formula II are useful, for instance, in modulating dopamine and serotonin neurotransmission and treating disorders that may benefit from the same, such as schizophrenia and depression.
CPC Classifications
C07D 207/14 A61K 31/40 A61K 31/402 A61P 25/22 A61P 25/24 C07B 59/004 C07D 207/09 C07B 2200/05
Filing Date
2025-06-11
Application No.
19235237
Related changes
Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.